Rotavirus News and Research

Latest Rotavirus News and Research

Outbreak of whooping cough mirrors challenges in developing world, global health official says

The outbreak of whooping cough in Texas, California, and other states this year underscores the critical importance of widespread vaccination coverage, both locally as well as around the world, said a leading global health official attending conferences on world affairs and immunization in Fort Worth this week.

29 Sep 2010

Immunization is critical to reduce child deaths

Immunising children against preventable diseases is critical to achieving United Nations-led goals to reduce child deaths, global health and development chiefs said in New York today.

22 Sep 2010

August is National Immunization and Cataract Awareness Month

Childhood immunizations keep our children safe from a number of serious diseases. This is a good time of year to make sure your child is up-to-date on all of his/her immunizations. Continue reading to find out which vaccines the Centers for Disease Control and Prevention (CDC) recommend for children 6 and under.

16 Aug 2010

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Two studies published online Thursday in the Lancet show that the rotavirus vaccine is safe and effective at preventing much of the gastrointestinal illness in developing countries, where rotavirus kills more than 400,000 children under age 5 annually, Reuters reports. Based on the findings in Asia and Africa, the studies' authors "urged the governments of developing nations to make the vaccines a priority," the news service writes.

7 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Pneumonia, diarrhea, and malaria cause death of 6 million of world's poorest children

A Johns Hopkins University scientist, whose team of researchers recently identified pneumonia, diarrhea, and malaria as the primary causes of death of 6 million of the world's poorest children, today called on leaders in donor and developing nations to take action to address the terrible death toll.

23 Jul 2010

NACI updates, strengthens statement related to the use of rotavirus vaccines in Canada

This week, the National Advisory Committee on Immunization updated and strengthened its statement related to the use of rotavirus vaccines in Canada. Rotavirus infection is the most common cause of severe gastroenteritis in children under the age of three. The NACI statement now includes Grade A recommendations (good evidence to recommend immunization) for healthy and preterm infants.

21 Jul 2010

New & improved rotavirus vaccine to be trialed in Melbourne

Now a vaccine is being developed against rotavirus in Melbourne. At present Australian children were given rotavirus vaccine at the age of six to eight weeks since 2007. This new vaccine will be applicable to infants from birth.

20 Jul 2010

Recent releases in global health

Looking ahead to AIDS 2010 which will be held in Vienna, Austria, July 18-23, a Lancet editorial writes that 2010 marks "the deadline set by global leaders to achieve universal access to HIV prevention, treatment, and care. Sadly, the world will not meet these ambitious goals." However, the latest issue of the Lancet "offers some new insights to progress," the editorial notes.

3 Jul 2010

ORS, zinc supplements and rotavirus vaccine can reduce diarrheal disease

Researchers from the Johns Hopkins Bloomberg School of Public Health urge wider use of oral rehydration solution (ORS), zinc supplementation and rotavirus vaccine to reduce the deaths from diarrheal disease worldwide.

2 Jul 2010

Combination MMRV vaccine associated with increased risk of febrile seizures

The combination vaccine for measles, mumps, rubella and chickenpox (MMRV) is associated with double the risk of febrile seizures for 1- to 2-year-old children compared with same-day administration of the separate vaccine for MMR (measles, mumps, rubella) and the varicella (V) vaccine for chicken pox, according to a Kaiser Permanente Division of Research study appearing online in the journal Pediatrics. A febrile seizure is a brief, fever-related convulsion but it does not lead to epilepsy or seizure disorders, researchers explained.

28 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

GAVI Alliance's plan to introduce new vaccine projects in the developing world "is under threat amid the international economic downturn," the Financial Times reports. "Subsidies to extend the use of vaccines against rubella, HPV to tackle cervical cancer, cholera and Japanese encephalitis in the developing world are among those likely to be cancelled or delayed," according to GAVI's CEO Julian Lob-Levyt, the newspaper writes.

17 Jun 2010

World Health Assembly news

Media outlets continue to track news emerging from the 63rd annual World Health Assembly (WHA) in Geneva.

20 May 2010

Cell Therapeutics' Special Meeting of Shareholders adjourned to June 4, 2010

Cell Therapeutics, Inc. today announced that the Company has adjourned today's Special Meeting of Shareholders to 10:00 am Pacific Daylight Time, Friday, June 4, 2010.

15 May 2010

Miami-area resident charged in $23M HIV infusion Medicare fraud scheme

A Miami-area resident who owned and operated an HIV infusion clinic was arrested today and charged for her alleged participation in a $23 million HIV infusion Medicare fraud scheme, the Departments of Justice and Health and Human Services (HHS) announced.

15 May 2010

Hiru Corporation completes Quarterly Report

Hiru Corporation publishes this Quarterly Report to serve the company's followers, investors and the public as a guidance through the past events and possible outcomes of these events in the upcoming quarter(s).

15 May 2010

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).

15 May 2010

U.S. healthcare practitioners can resume use of Rotarix, says FDA

GlaxoSmithKline announced that the Food and Drug Administration has determined that U.S. healthcare practitioners can resume the use of Rotarix (Rotavirus Vaccine, Live, Oral), effective immediately. This action supersedes the FDA's recommendation from March 22, 2010 and reflects the agency's assessment that the presence of porcine circovirus type 1 in the vaccine poses no safety risk.

15 May 2010

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.

15 May 2010

Rotavirus News and Research

Latest Rotavirus News and Research

Outbreak of whooping cough mirrors challenges in developing world, global health official says

Immunization is critical to reduce child deaths

August is National Immunization and Cataract Awareness Month

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Merck reports strong bottom-line performance in second quarter

Pneumonia, diarrhea, and malaria cause death of 6 million of world's poorest children

NACI updates, strengthens statement related to the use of rotavirus vaccines in Canada

New & improved rotavirus vaccine to be trialed in Melbourne

Recent releases in global health

ORS, zinc supplements and rotavirus vaccine can reduce diarrheal disease

Combination MMRV vaccine associated with increased risk of febrile seizures

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

World Health Assembly news

Cell Therapeutics' Special Meeting of Shareholders adjourned to June 4, 2010

Miami-area resident charged in $23M HIV infusion Medicare fraud scheme

Hiru Corporation completes Quarterly Report

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

U.S. healthcare practitioners can resume use of Rotarix, says FDA

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Rotavirus News and Research

Latest Rotavirus News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in